Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.

Investigational new drugs - 1 Apr 2018

Kipper Franciele Cristina, Silva Andrew Oliveira, Marc André Luis, Confortin Gláucia, Junqueira Augusto Valadão, Neto Eliseu Paglioli, Lenz Guido

Abstract excerpt

Glioblastoma (GBM) is a very aggressive tumor that has not had substantial therapeutic improvement since the introduction of temozolomide (TMZ) in combination with radiotherapy. Combining TMZ with other chemotherapeutic agents is a strategy that could be further explored for GBM. To search for molecular predictors of TMZ resistance, the TCGA (The Cancer Genome Atlas) database was utilized to assess the impact of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthelmintics
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cellular Senescence

Share to Drug Resistance, Neoplasm

Share to Glioma

Share to Polyploidy

Share to Temozolomide

Share to Vinblastine

Source

Identifiers

PMID: 28852916
DOI: 10.1007/s10637-017-0503-7

Genes

AKT2
FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.PMID 28852916Read ↗

Cellular and Molecular Comparison of Glioblastoma Multiform Cell LinesSemantic proximity Read ↗

Downregulated the expression of DNMT3B by suppressing PI3K/Akt signaling pathway and enhances the chemosensitivity of glioblastoma to temozolomide.Semantic proximity Read ↗

Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitroSemantic proximity Read ↗

Recent Approaches to Improve the Antitumor Efficacy of TemozolomideSemantic proximity Read ↗

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.Semantic proximity Read ↗

Vemurafenib Sensitizes Melanoma Cells to Temozolomide by Downregulating MGMT Expression.Semantic proximity Read ↗

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant gliomaSemantic proximity Read ↗

Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genesSemantic proximity Read ↗

The Temozolomide-Doxorubicin paradox in Glioblastoma in vitro-in silico preclinical drug-screeningSemantic proximity Read ↗

Temozolomide resistance mechanisms: unveiling the role of translesion DNA polymerase kappa in glioblastoma spheroidsin vitroSemantic proximity Read ↗

A combination of IFN-β and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulationSemantic proximity Read ↗

Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.